The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
-
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States, 80045
Colorado Blood Cancer Institute, Denver, Colorado, United States, 80218
Local Institution - 0048, New Haven, Connecticut, United States, 06520
Mayo Clinic in Florida, Jacksonville, Florida, United States, 32224
University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami, Florida, United States, 33136
Local Institution - 0053, Chicago, Illinois, United States, 60607
Local Institution - 0030, Baltimore, Maryland, United States, 21287
Local Institution - 0038, Boston, Massachusetts, United States, 02115
Local Institution - 0046, Boston, Massachusetts, United States, 02115
Local Institution - 0033, Worcester, Massachusetts, United States, 01655
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2027-11-15